Patents by Inventor Eugen Koren
Eugen Koren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220120759Abstract: Surface plasmon resonance-based methods for detecting and characterizing preexisting and/or treatment-induced anti-viral vector antibodies against viral vector-based gene therapy compositions in a biological sample from a subject are described.Type: ApplicationFiled: January 31, 2020Publication date: April 21, 2022Inventors: Eugen KOREN, Tyler CHUANG, Chad MORRIS, M. Travis HARRISON, Rajiv MAHADEVAN
-
Patent number: 9624528Abstract: A method of determining the thrombogenicity of an implantable medical device is disclosed. The implanted device is exposed in vitro to platelet rich plasma, the activity of an indicator is assayed, and the thrombogenicity is determined.Type: GrantFiled: October 20, 2015Date of Patent: April 18, 2017Assignee: Abbott Cardiovascular Systems Inc.Inventors: Mirna Koscec, Eugen Koren
-
Publication number: 20160076077Abstract: A method of determining the thrombogenicity of an implantable medical device is disclosed. The implanted device is exposed in vitro to platelet rich plasma, the activity of an indicator is assayed, and the thrombogenicity is determined.Type: ApplicationFiled: October 20, 2015Publication date: March 17, 2016Inventors: Mirna Koscec, Eugen Koren
-
Patent number: 9193987Abstract: A method of determining the thrombogenicity of an implantable medical device is disclosed. The implanted device is exposed in vitro to platelet rich plasma, the activity of an indicator is assayed, and the thrombogenicity is determined.Type: GrantFiled: April 18, 2014Date of Patent: November 24, 2015Assignee: Abbott Cardiovascular Systems Inc.Inventors: Mirna Koscec, Eugen Koren
-
Publication number: 20150299759Abstract: A method of determining the thrombogenicity of an implantable medical device is disclosed. The implanted device is exposed in vitro to platelet rich plasma, the activity of an indicator is assayed, and the thrombogenicity is determined.Type: ApplicationFiled: April 18, 2014Publication date: October 22, 2015Inventors: Mirna Koscec, Eugen Koren
-
Patent number: 7098036Abstract: Compositions and methods using antibodies which are immunoreactive with specific apolipoproteins to determine the concentrations of lipoproteins such as HDL and LDL, and/or apolipoproteins in human blood, serum or plasma sample, are described. Monoclonal antibodies (MAbs) are described that specifically bind to epitopes present in apolipoproteins and lipoproteins, enabling rapid and reliable determinations of levels of specific blood lipoprotein and/or apolipoprotein levels, including Apo B-100, Apo A-I, Apo A-II, Apo C-III, and Apo E, and thereby determination of relative ratios of HDL and LDL and LpaI and LpaII. In a preferred embodiment, the compositions are strips of a solid phase material coated with one or more of the antibodies and are referred to herein as “dipsticks”. The dipsticks specifically bind a lipoprotein or apolipoprotein when dipped into a protein sample.Type: GrantFiled: November 13, 1997Date of Patent: August 29, 2006Assignee: Okalahoma Medical Research FoundationInventors: Eugen Koren, Mirna Koscec
-
Publication number: 20040209324Abstract: The invention provides for methods of modifying immunodominant epitopes on polypeptides, preferably polypeptides intended for therapeutic use. Knowledge of immunodominant epitopes prior to clinical use of polypeptides would be useful to design and engineer less immunogenic molecules. The invention provides for methods of identifying immunodominant epitopes and modifying an immunodominant epitope to reduce the immune response to the polypeptide while still retaining a substantial therapeutic activity of the polypeptide. The modified polypeptides are useful therapeutically.Type: ApplicationFiled: December 8, 2003Publication date: October 21, 2004Applicant: Genentech, Inc.Inventors: Eugen Koren, John Hok Nin Lowe
-
Publication number: 20040053321Abstract: Compositions and methods using antibodies which are immunoreactive with specific apolipoproteins to determine the concentrations of lipoproteins such as HDL and LDL, and/or apolipoproteins in human blood, serum or plasma sample, are described. Monoclonal antibodies (MAbs) are described that specifically bind to epitopes present in apolipoproteins and lipoproteins, enabling rapid and reliable determinations of levels of specific blood lipoprotein and/or apolipoprotein levels, including Apo B-100, Apo A-I, Apo A-II, Apo C-III, and Apo E, and thereby determination of relative ratios of HDL and LDL and LpaI and LpaII. In a preferred embodiment, the compositions are strips of a solid phase material coated with one or more of the antibodies and are referred to herein as “dipsticks”. The dipsticks specifically bind a lipoprotein or apolipoprotein when dipped into a protein sample.Type: ApplicationFiled: December 24, 1996Publication date: March 18, 2004Applicant: PATREA L PABST HOLLAND AND KNIGHT LLPInventors: EUGEN KOREN, MIRNA KOSCEC
-
Patent number: 6673580Abstract: The invention provides for methods of modifying immunodominant epitopes on polypeptides, preferably polypeptides intended for therapeutic use. Knowledge of immunodominant epitopes prior to clinical use of polypeptides would be useful to design and engineer less immunogenic molecules. The invention provides for methods of identifying immunodominant epitopes and modifying an immunodominant epitope to reduce the immune response to the polypeptide while still retaining a substantial therapeutic activity of the polypeptide. The modified polypeptides are useful therapeutically.Type: GrantFiled: June 1, 2001Date of Patent: January 6, 2004Assignee: Genentech, Inc.Inventors: Eugen Koren, John Hok Nin Lowe
-
Publication number: 20030131365Abstract: Methods to manipulate animals such as pigs, and the animals and tissues thereby derived, to reduce their immunogenicity following implantation into humans, are described. These methods are based on the discovery that certain carbohydrate structures on pig tissues, which require expression of the gene encoding the &agr; 1→3 galactosyl transferase enzyme, are targets for natural preformed antibodies of humans and elicit further antibody production in humans, while other carbohydrate structures do not or do so in a reduced amount. In the preferred embodiment, animals are produced by homologous recombination of the gene encoding &agr; 1→3 galactosyl transferase in embryonic stem cells or by microinjection into embryos of sequences eliminating or decreasing expression of &agr; 1→3 galactosyl transferase. In alternative embodiments, animals are produced having reduced amounts of →1→3 galactosyl epitopes or epitopes which are masked by sialylation or fucosylation.Type: ApplicationFiled: June 12, 2002Publication date: July 10, 2003Applicant: INTEGRIS Baptist Medical Center, Inc.Inventors: David K. C. Cooper, Eugen Koren
-
Publication number: 20030077756Abstract: The invention provides for methods of modifying immunodominant epitopes on polypeptides, preferably polypeptides intended for therapeutic use. Knowledge of immunodominant epitopes prior to clinical use of polypeptides would be useful to design and engineer less immunogenic molecules. The invention provides for methods of identifying immunodominant epitopes and modifying an immunodominant epitope to reduce the immune response to the polypeptide while still retaining a substantial therapeutic activity of the polypeptide. The modified polypeptides are useful therapeutically.Type: ApplicationFiled: June 1, 2001Publication date: April 24, 2003Inventors: Eugen Koren, John Hok Nin Lowe
-
Publication number: 20020155105Abstract: Treatments have been developed for lupus patients using either anti-ID antibodies to dsDNA to block anti-dsDNA antibodies and/or kill the B cells producing the anti-dsDNA antibodies or ribosomal protein S1 peptides immunoreactive with anti-dsDNA antibodies. Examples demonstrate that (1) anti-dsDNA antibodies are cross-reactive with ribosomal protein S1, (2) anti-dsDNA antibodies suppress protein synthesis, presumably through inhibition of mRNA translation initiation, and (3) a normal human sera contains an anti-idiotypic antibody (anti-Id) to anti-dsDNA antibodies isolated from SLE patients which blocked the interactions between the anti-Id antibody fragment (Fab2) and various anti-dsDNA preparations.Type: ApplicationFiled: January 23, 2001Publication date: October 24, 2002Inventors: Morris Reichlin, Eugen Koren
-
Publication number: 20020152488Abstract: Methods to manipulate animals such as pigs, and the animals and tissues thereby derived, to reduce their immunogenicity following implantation into humans, are described. These methods are based on the discovery that certain carbohydrate structures on pig tissues, which require expression of the gene encoding the &agr;1→3 galactosyl transferase enzyme, are targets for natural preformed antibodies of humans and elicit further antibody production in humans, while other carbohydrate structures do not or do so in a reduced amount. In the preferred embodiment, animals are produced by homologous recombination of the gene encoding &agr;1→3 galactosyl transferase in embryonic stem cells or by microinjection into embryos of sequences eliminating or decreasing expression of &agr;1→3 galactosyl transferase. In alternative embodiments, animals are produced having reduced amounts of &agr;1→3 galactosyl epitopes or epitopes which are masked by sialylation or fucosylation.Type: ApplicationFiled: September 4, 2001Publication date: October 17, 2002Applicant: Baptist Medical Center of Oklahoma, Inc.Inventors: David K. C. Cooper, Eugen Koren
-
Publication number: 20020098597Abstract: Compositions and methods using antibodies which are immunoreactive with specific apolipoproteins to determine the concentrations of lipoproteins such as HDL and LDL, and/or apolipoproteins in human blood, serum or plasma sample, are described. Monoclonal antibodies (MAbs) are described that specifically bind to epitopes present in apolipoproteins and lipoproteins, enabling rapid and reliable determinations of levels of specific blood lipoprotein and/or apolipoprotein levels, including Apo B-100, Apo A-I, Apo A-II, Apo C-III, and Apo E, and thereby determination of relative ratios of HDL and LDL and LpaI and LpaII. In a preferred embodiment, the compositions are strips of a solid phase material coated with one or more of the antibodies and are referred to herein as “dipsticks”. The dipsticks specifically bind a lipoprotein or apolipoprotein when dipped into a protein sample.Type: ApplicationFiled: November 13, 1997Publication date: July 25, 2002Inventors: EUGEN KOREN, MIRNA KOSCEC
-
Patent number: 6342218Abstract: Treatments have been developed for lupus patients using either anti-ID antibodies to dsDNA to block anti-dsDNA antibodies and/or kill the B cells producing the anti-dsDNA antibodies or ribosomal protein S1 peptides immunoreactive with anti-dsDNA antibodies. Examples demonstrate that (1) anti-dsDNA antibodies are cross-reactive with ribosomal protein S1, (2) anti-dsDNA antibodies suppress protein synthesis, presumably through inhibition of mRNA translation initiation, and (3) a normal human sera contains an anti-idiotypic antibody (anti-Id) to anti-dsDNA antibodies isolated from SLE patients which blocked the interactions between the anti-Id antibody fragment (Fab2) and various anti-dsDNA preparations.Type: GrantFiled: February 14, 1997Date of Patent: January 29, 2002Assignee: Oklahoma Medical Research FoundationInventors: Morris Reichlin, Eugen Koren
-
Patent number: 6331658Abstract: Methods to manipulate animals such as pigs, and the animals and tissues thereby derived, to reduce their immunogenicity following implantation into humans, are described. These methods are based on the discovery that certain carbohydrate structures on pig tissues, which require expression of the gene encoding the &agr; 1→3 galactosyl transferase enzyme, are targets for natural preformed antibodies of humans and elicit further antibody production in humans, while other carbohydrate structures do not or do so in a reduced amount. In the preferred embodiment, animals are produced by homologous recombination of the gene encoding &agr; 1→3 galactosyl transferase in embryonic stem cells or by microinjection into embryos of sequences eliminating or decreasing expression of &agr; 1→3 galactosyl transferase. In alternative embodiments, animals are produced having reduced amounts of &agr; 1→3 galactosyl epitopes or epitopes which are masked by sialylation or fucosylation.Type: GrantFiled: January 27, 1995Date of Patent: December 18, 2001Assignees: Integris Baptist Medical Center, Inc., Oklahoma Medical Research FoundationInventors: David K. C. Cooper, Eugen Koren
-
Patent number: 6280944Abstract: Assays that are prognostic for patients that will develop nephritis have been developed where patient serum is screened for the presence of anti-dsDNA antibodies that are cross reactive with A and D SnRNP proteins. The assays are based on the use of either peptides containing epitopes bound by the anti-dsDNA antibodies, or the antigens for the antibodies, A and D SnRNP proteins. Therapeutic compositions have also been developed using either antibodies that block the pathogenicity of the anti-dsDNA antibodies, such as the naturally occurring anti-La/SSB, anti-Ro/SSA and anti-U1RNP antibodies that are cross reactive with the anti-dsDNA or using the peptides or A and D proteins to induce tolerance.Type: GrantFiled: August 2, 1999Date of Patent: August 28, 2001Assignee: Oklahoma Medical Research FoundationInventors: Morris Reichlin, Eugen Koren, Wei Zhang
-
Patent number: 6107045Abstract: Compositions and methods using antibodies which are immunoreactive with specific apolipoproteins to determine the concentrations of lipoproteins such as HDL and LDL, and/or apolipoproteins in human blood, serum or plasma sample, are described. Monoclonal antibodies (MAbs) are described that specifically bind to epitopes present in apolipoproteins and lipoproteins, enabling rapid and reliable determinations of levels of specific blood lipoprotein and/or apolipoprotein levels, including Apo B-100, Apo A-I, Apo A-II, Apo C-III, and Apo E, and thereby determination of relative ratios of HDL and LDL and LpaI and LpaII. In a preferred embodiment, the compositions are strips of a solid phase material coated with one or more of the antibodies and are referred to herein as "dipsticks". The dipsticks specifically bind a lipoprotein or apolipoprotein when dipped into a protein sample.Type: GrantFiled: June 30, 1994Date of Patent: August 22, 2000Assignee: Oklahoma Medical Research FoundationInventors: Eugen Koren, Mirna Koscec
-
Patent number: 5728812Abstract: Antibodies directed against idiotypes on naturally occurring human anti-animal antibodies are disclosed for use in inhibiting xenograft rejection in human patients. An effective quantity of these anti-idiotypic antibodies is injected into the actual or potential xenograft recipient in order to bind to the idiotypes expressed on anti-animal antibodies as well as subpopulations of B lymphocytes, to inhibit hyperacute rejection of transplanted animal tissues or organs by the human patient. Alternatively, anti-idiotypic antibodies are used in the form of immunoaffinity columns to deplete anti-animal antibodies from the recipient's serum. Methods of making mouse monoclonal, mouse recombinant, and human recombinant anti-idiotypic antibodies are described, as well as immunoaffinity columns containing immobilized anti-idiotypic antibodies.Type: GrantFiled: June 2, 1995Date of Patent: March 17, 1998Assignees: Oklahoma Medical Research Foundation, Baptist Medical Center of Oklahoma, Inc.Inventors: Eugen Koren, David K. C. Cooper
-
Patent number: 5681700Abstract: Assays that are prognostic for patients that will develop nephritis have been developed where patient serum is screened for the presence of anti-dsDNA antibodies that are cross reactive with A and D SnRNP proteins. The assays are based on the use of either peptides containing epitopes bound by the anti-dsDNA antibodies, or the antigens for the antibodies, A and D SnRNP proteins. Therapeutic compositions have also been developed using either antibodies that block the pathogenicity of the anti-dsDNA antibodies, such as the naturally occurring anti-La/SSB and anti-U.sub.1 RNP antibodies that are cross reactive with the anti-dsDNA or using the peptides or A and D proteins to induce tolerance.Type: GrantFiled: May 25, 1994Date of Patent: October 28, 1997Assignee: Oklahoma Medical Research FoundationInventors: Morris Reichlin, Eugen Koren